Latanoprost and Respiratory Function in Asthmatic Patients

Abstract

To evaluate the effects of single and multiple administrations of the ocular hypotensive drug latanoprost on respiratory function, asthma symptoms, and use of asthma medication in patients with bronchial asthma. Methods: Twenty-four stable patients with asthma (forced expiratory volume in 1 second: 70% to 90% of predicted and a minimum of 10% reversibility after inhalation of albuterol sulfate) with no previous exposure to inhaled corticosteroids participated in this randomized, double-masked crossover trial. Patients received latanoprost, 0.005%, or placebo, 1 drop per day, in each eye during two 6-day treatment periods separated by a 2-week washout period. Acute latanoprost or placebo provocation, methacholine chloride airway reactivity, and ␤ 2-stimulator reversibility tests were performed. Main Outcome Measures: Morning and evening peak expiratory flow, spirometric performance throughout treatment periods and during different provocation tests, asthma symptoms, and use of asthma medications were evaluated. Results: There were no statistically significant differences between treatments in morning and evening peak expiratory flow, scored daytime and nocturnal asthma symptoms, or daily consumption of asthma medication. During placebo provocation, there was a small increase in forced expiratory volume in 1 second that was not seen during latanoprost provocation. This small difference (−0.09 L) was statistically significant but without clinical importance. Conclusions: Resting and provoked airway function and asthma symptoms were unaffected by latanoprost treatment in patients with asthma with no previous exposure to corticosteroids. Latanoprost can be used in patients with glaucoma and concomitant bronchial asthma.

Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension

“…Therefore, caution is necessary in the use of timolol in such patients. In contrast, latanoprost does not alter heart rate and blood pressure,29 30 35 and does not affect respiratory function in asthmatic patients 55. The major adverse reaction to latanoprost is an increase in iris pigmentation.…”

The Comparative Cardiovascular, Pulmonary, Ocular Blood Flow, and Ocular Hypotensive Effects of Topical Travoprost, Bimatoprost, Brimonidine, and Betaxolol

“…Heart rate and blood pressure were monitored every minute for the first 15 minutes. Monitoring of blood pressure and heart rate continued in the recovery period every 3 minutes for another 15 minutes (minutes [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. The treadmill test was recorded with a device (Pulse Medicals, Norristown, PA) connected to a computer, using a specialized software.…”

“…In the human lung, the potent bronchoconstrictors PGD-2 and PGF 2␣ are derived from mast cells. Acute asthma is associated with an increased concentration of PGF 2␣ metabolites in lung tissue, blood, and urine (16). Thus, newly introduced PGF 2␣ analogs deserve investigation of cardiopulmonary effects.…”

Effects of Latanoprost and Betaxolol on Cardiovascular and Respiratory Status of Newly Diagnosed Glaucoma Patients

“…These medications may drain down the nasolacrimal duct to be absorbed by the nasopharyngeal mucosa into the systemic circulation [2,3,4,5]. By means of blood circulation, some topically applied medications have the potential of reaching high concentrations causing bradycardia and respiratory impairment [5,6,7].…”

“…Among these, latanoprost is reported to have the additional advantage of having no or very few systemic side effects [4,5,6,13,14,15]. …”